Estrogen and the selective estrogen receptor modulator (SERM) protection against cell death in estrogen receptor alpha and beta expressing U2OS cells

Molecular and Cellular Endocrinology

Volumn 289, Issue 1-2, 2008, Pages 38-48

  Kallio, Anu ^a   Guo, Tao ^a,b,c   Lamminen, Elisa ^a   Seppänen, Jani ^a   Kangas, Lauri ^d   Väänänen, H Kalervo ^a   Härkönen, Pirkko ^e  

^a UNIVERSITY OF TURKU   (Finland)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c Key lab for Bio targeted Therapy of Hubei Province   (China)

^d Hormos Medical Ltd   (Finland)

^e LUND UNIVERSITY   (Sweden)

Author keywords

Estradiol; Estrogen receptor; IL 6; OPG; Osteoblast; U2OS

Indexed keywords

1,3,5 TRIS(4 HYDROXYPHENYL) 4 PROPYLPYRAZOLE; DIARYLPROPIONITRILE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ETOPOSIDE; HORMONE RECEPTOR STIMULATING AGENT; INTERLEUKIN 6; OSPEMIFENE; OSTEOCLAST DIFFERENTIATION FACTOR; RALOXIFENE; TAMOXIFEN;

APOPTOSIS; ARTICLE; CELL DEATH; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ETOPOSIDE; HUMANS; INTERLEUKIN-6; OSTEOBLASTS; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 45049086100     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2008.03.005     Document Type: Article

References (78)

1. Bashir A., Mak Y.T., Sankaralingam S., et al. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene. Steroids 70 (2005) 847-855
2. Bord S., Ireland D.C., Beavan S.R., and Compston J.E. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone 32 (2003) 136-141
3. Brady H., Doubleday M., Gayo-Fung L., Hickman M., Khammungkhune S., Kois A., Lipps S., Pierece S., Richard N., Shevlin G., Sutherland M.K., Anderson D., Bhagwat S., and Stein B. Differential response of estrogen receptors α and β to SP500263, a novel potent selective estrogen receptor modulator. Mol. Pharm. 61 (2002) 562-568
4. Bruder J.M., Sobek L., Oettel M., et al. Dehydroepiandrosterone stimulates the ERE. J. Steroid Biochem. Mol. Biol. 62 (1997) 461-466
5. Bynoe M., Grimaldi C., and Diamond B. Estrogen up-regulates Bcl-2 and blocks tolerance induction of naive B cells. Proc. Natl. Acad. Sci. 97 (2000) 2703-2708
6. Chen J.-R., Haley R.L., Hidestrand M., Shankar K., Liu X., Lumpkin C.K., Simpson P., Badger T., and Ronis M. Estradiol protects against ethanol-induced bone loss by inhibiting up-regulation of receptor activator of nuclear factor-κB ligand in osteoblasts. J. Pharm. Exp. Ther. 319 (2006) 1182-1190
7. Cheung J., Mak Y.T., Papaioannou S., Evans B.A.J., Fogelman I., and Hampson G. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene. J. Endocrinol. 177 (2003) 423-433
8. Choi K., Kang S., Tai C., Auersperg N., and Leung P. Estradiol up-regulates antiapoptotic Bcl-2 messenger ribonucleic acid and protein in tumorigenic ovarian surface epithelium cells. Endocrinology 142 (2001) 2351-2360
9. Cicek M., and Oursler M.J. Breast cancer bone metastasis and current small therapeutics. Cancer Metastasis Rev. 25 (2006) 635-644
10. Compston J.E. Sex steroids and bone. Physiol. Rev. 81 (2001) 419-447
11. De Vita F., Orditura M., Auriemma A., Infusino S., Roscigno A., and Catalano G. Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncol. Rep. 5 (1998) 649-692
12. Edwards D.P. Regulation of signal transduction pathways by estrogen and progesterone. Annu Rev. Physiol. 67 (2005) 335-376
13. Ettinger B., Black D.M., Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA 282 (1999) 637-645
14. Fisher B., Constantino J.P., Wickerham C.D., et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J. Natl. Cancer Inst. 90 (1998) 1371-1388
15. Fuqua S.A., Schiff R., Parra I., et al. Expression of wild-type ERβ and variant isoforms in human breast cancer. Cancer Res. 59 (1999) 5425-5428
16. Gradishar W., Glusman J., Lu Y., Vogel C., Cohen F.J., and Sledge Jr. G.W. Effects of high dose raloxifene in selected patients with advanced breast carcinoma. Cancer 88 (2000) 2047-2053
17. Gu G., Hentunen T.A., Nars M., Härkönen P.L., and Väänänen H.K. Estrogen protects primary osteocytes against glucocorticoid-induced apoptosis. Apoptosis 10 (2005) 583-595
18. Haynes M., Sinha D., Russell K., Collinge M., Fulton D., Morales-Ruiz M., Sessa W.C., and Bender J.R. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3K-kinase-Akt pathway in human endothelial cells. Circ. Res. 87 (2000) 677-682
19. Hofbauer L.C., Khosla S., and Dunstan C.R. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140 (1999) 4367-4370
20. Jilka R.L., Weinstein R.S., Bellido T., Parfitt A.M., and Manolagas S.C. Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J. Bone Miner. Res. 13 (1998) 793-802
21. Jilka R.L., Weinstein R.S., Parfitt A.M., and Manolagas S.C. Quantifying osteoblast and osteocyte apoptosis: challenges and rewards. J. Bone Miner. Res. 22 (2007) 1492-1501
22. Jordan V.C. Designer estrogens. Sci. Am. 279 (1998) 60-67
23. Kameda T., Ishikawa H., and Tsutsumi T. Detection and characterization of apoptosis in osteoclasts in vitro. Biochem. Biophys. Res. Commun. 207 (1995) 753-760
24. Kawakami A., Eguchi K., Matsuoka N., Tsuboi M., koji T., and Urayama S. Fas and Fas ligand interaction is necessary for human osteoblast apoptosis. J. Bone Miner. Res. 12 (1997) 1637-1646
25. Kawakami A., Nakashima T., Tsuboi M., Urayama S., Matsuoka N., Ida H., Kawabe Y., Sakai H., Migita K., Aoyagi T., Nakashima M., Maeda K., and Egushi K. Insulin-like growth factor I stimulates proliferation and Fas-mediated apoptosis of human osteoblasts. Biochem. Biophys. Res. Commun. 247 (1998) 46-51
26. Khosla S., Atkinson E.J., Dunstan C.R., and O'Fallon W.M. Effect of estrogen versus testosterone on circulating OPG and other cytokine levels in normal elderly men. J. Clin. Endocrinol. Metab. 87 (2002) 1550-1554
27. Kian Tee M., Rogatsky I., Tzagarakis-Foster C., Cvoro A., An J., Christy R., Ymamamoto K., and Leitman D. Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors α and β. Mol. Biol. Cell 15 (2004) 1262-1272
28. Komi J., Heikkinen J., Rutanen E.M., Halonen K., Lammintausta R., and Ylikorkala O. Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women. Gynecol. Endocrinol. 18 (2004) 152-158
29. Komi J., Lankinen K., DeGregorio M., Heikkinen J., Saarikoski S., Tuppurainen M., Halonen K., Lammintausta R., Väänänen K., Ylikorkala O., and Erkkola R. Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women. J. Bone Miner. Metab. 24 (2006) 314-318
30. Kousteni S., Bellido T., Plotkin L.I., O'Brien C.A., Bodenner D.L., Han L., Han K., DiGregorio G.B., Katzenellenbogen B.S., Katzenellenbogen P.K., Roberson P.K., Weinstein R.S., Jilka R.L., and Manolagas S.C. Nongenotropic, sex-nonspecific signalling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104 (2001) 719-730
31. Kousteni S., Han L., Chen J.-R., Almeida M., Plotkin L., Bellido T., and Manolagas S. Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J. Clin. Invest. 111 (2003) 1651-1664
32. Li F., Zhang D., and Fujise K. Characterization of fortilin, a novel antiapoptotic protein. J. Biol. Chem. 276 (2001) 47542-47549
33. Lindberg M.K., Erlandsson M., Alatalo S.L., Windahl S., Andersson G., Halleen J.M., Carlsten H., Gustafsson J.A., and Ohlsson C. Estrogen receptor alpha, but not estrogen receptor beta, is involved in the regulation of the OPG/RANKL (osteoprotegerin/receptor activator of NF-kappa B ligand) ratio and serum interleukin-6 in male mice. J. Endocrinol. 171 (2001) 425-433
34. Love R.R., Barden H.S., Mazess R.B., Epstein S., and Chappell R.J. Effect of Tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch. Intern. Med. 28 (1994) 2585-2588
35. Manolagas S.C., Kousteni S., and Jilka R.L. Sex steroids and bone. Recent Prog. Horm. Res. 57 (2002) 385-409
36. Manolagas S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21 (2000) 115-137
37. Manolagas S.C. Role of cytokines in bone resorption. Bone 17 (1995) 63S-67S
38. McCauley L.K., Tözum T.F., Kozloff M., Koh-Paige A.J., Chen C., Demeshkjen M., Cronovich H., Richard V., Keller E.T., Rosol T.J., and Goldstein S.A. Transgenic models of metabolic bone disease: impact of estrogen receptor deficiency on skeletal metabolism. Connect. Tissue Res. 44 (2003) 250-263
39. McDougall K.E., Perry M.J., Gibson R.L., Colley S.M., Korach K.S., and Tobias J.H. Estrogen receptor-alpha dependency of estrogen's stimulatory action on cancellous bone formation in male mice. Endocrinology. 144 (2003) 1994-1999
40. Messalli E., Mainini G., Scaffa C., Cafiero A., Salzillo P.L., Ragucci A., and Cobellis L. Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women. Maturitas 56 (2007) 38-44
41. Michael H., Härkönen P.L., Kangas L., Väänänen H.K., and Hentunen T.A. Differential effects of selective oestrogen receptor modulators (SERMs) on human osteoclasts in vitro. Br. J. Pharm. (2007) 1-12
42. Monroe D., Getz B., Johnsen S., Riggs B., Khosla S., and Spelsberg T. Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ERα or ERβ. J. Cell. Biochem. 90 (2003) 315-326
43. Monroe D., Secreto F., Hawse J., Subramaniam M., Khosla L., and Spelsberg T.C. Estrogen receptor isoform-specific regulation of the retinoblastoma-binding protein 1 (RBBP1) gene: roles of AF1 and enhancer elements. J. Biol. Chem. 281 (2006) 28596-28604
44. Nakashima T., Sasaki H., Tuboi M., Kawakami A., Fyjiyama K., and Kiriyama T. Inhibitory effect of glugocorticoid for osteoblast apoptosis induced by activated peripheral blood mononuclear cells. Endocrinology 139 (1998) 2032-2040
45. Olijslagers S., Zhang Y.-H., Backendorf C., and Noteborn M. Additive cytotoxic effect of apoptin and chemotherapeutic agents paclitaxel and etoposide on human tumour cells. Basic Clin. Pharmacol. Toxicol. 100 (2007) 127-131
46. Olivier S., Fillet M., Malaise M., Piette J., Bours V., Merville M.P., and Franchimont M. Sodium nitroprusside-induced osteoblast apoptosis is mediated by long chain ceramide and is decreased by raloxifene. Biochem. Pharmacol. 69 (2005) 891-901
47. Parikka V., Peng Z., Hentunen T., Risteli J., Elo T., Väänänen H.K., and Härkönen P. Estrogen responsiveness of bone formation in vitro and altered bone phenotype in aged estrogen receptor-alpha-deficient male and female mice. Eur. J. Endocrinol. 152 (2005) 301-314
48. Perillo B., Sasso A., Abbondanza C., and Palumbo G. 17beta-Estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol. Cell Biol. 20 (2000) 2890-2901
49. Plotkin L., Manolagas S., and Bellido T. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone 39 (2006) 443-452
50. Powles T.J., Hickish T., Kanis J.A., Tidy A., and Ashley S. Effect of Tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J. Clin. Oncol. 14 (1996) 78-84
51. Qu Q., Härkönen P.L., and Väänänen H.K. Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in bone marrow culture. J. Cell. Biochem. 73 (1999) 500-507
52. Qu Q., Zheng H., Dahllund J., et al. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level and reproductive tissues in intact and ovariectomized rats. Endocrinology 141 (2000) 809-820
53. Radmacher M.D., and Simon R. Estimation of tamoxifenśs efficiency for preventing the formation and growth of breast tumors. J. Natl. Cancer Inst. 92 (2000) 48-53
54. Ramalho A.C., Couttet P., Baudoin C., Morieux C., Graulet A.M., de Vernejoul M.C., and Cohen-Solal M.E. Estradiol and raloxifene decrease the formation of multinucleate cells in human bone marrow cultures. Eur. Cytokine Netw. 13 (2002) 99-145
55. Riggs B.L., Khosla S., and Melton L.J. Sex steroids and the construction and conservation of adult skeleton. Endocr. Rev. 23 (2002) 279-302
56. Saika M., Inoue D., Kido S., and Matsumoto T. 17β-Estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-α. Endocrinology 142 (2001) 2205-2212
57. Sandoval R., Xue J., Pilkinton M., Salvi D., Kiyokawa H., and Colamoncini O. Induction of apoptosis requires ARF but not p53 in osteosarcoma cell lines. J. Biol. Chem. 279 (2004) 32275-32280
58. Sims N., Clement-Lacroix P., Minet D., Fraslon-Vanhulle C., gaillard-Kelly M., Resche-Rigon M., and Baron R. A functional androgen receptor is not sufficient to allow estradiol to protect bone after gonadectomy in estradiol receptor-deficient mice. J. Clin. Invest. 111 (2003) 1319-1327
59. Spelsberg T.C., Subramamiam M., Riggs B.L., and Khosla. The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. Mol. Endocrinol. 13 (1999) 819-828
60. Stossi F., Barnett D., Frasor J., Komm B., Lyttle R., and Katzenellenbogen B. Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) α or ERβ in human osteosarcoma cells: distinct and common target genes for these receptors. Endocrinology 145 (2004) 3473-3486
61. Sutherland M.K., Hui D.U., Rao L.G., Wylie J.N., and Murray T.M. Immunohistochemical localization of the estrogen receptor in human osteoblastic SaOS-2 cells, association of receptor levels with alkaline phosphatase activity. Bone 18 (1996) 361-369
62. Syed F., and Khosla S. Mechanisms of sex steroid effects on bone. Biochem. Biophys. Res. Commun. 328 (2005) 688-696
63. Taranta A., Brama M., teti A., De Luca V., Scandurra R., Spera G., Agnusdei D., Termine J., and Migliaccio S. The selective estrogen receptor modulatorm Raloxifene regulates osteoclast and osteoblasts activity in vitro. Bone 30 (2002) 368-376
64. Taras T.L., Wurz G.T., and DeGregorio M.W. In vitro and in vivo biologic effects of ospemifene (FC-1271a) in breast cancer. J. Steroid Biochem. Mol. Biol. 77 (2001) 271-279
65. Tozava K., Okamoto T., Hayashi Y., Sasaki S., Kawai N., and Kohri K. N-Acetyl-l-cysteine enhances chemotherapeutic effect on prostate cancer cells. Urol. Res. 30 (2002) 53-58
66. Urayama S., Kawakami A., Nakashima T., Tsuboi M., Yamasaki S., Hida A., Ichinose Y., Nakamura H., Ejima E., Aoyagi t, Nakamura T., Migita K., Kawabe y, and Eguchi K. Effect of vitamin K2 on osteoblast apoptosis: vitamin K2 inhibits apoptotic cell death of human osteoblasts induced by Fas, proteasome inhibitor, etoposide, and staurosporine. J. Lab. Clin. Med. 136 (2000) 181-193
67. Van Essen H.W., Holzmann P.J., Blankenstein M.A., Lips P., and Bravenboer N. Effect of raloxifene treatment on osteocyte apoptosis in postmenopausal women. Calcif. Tissue Int. 81 (2007) 183-190
68. Verdengh M., Johnsson I.M., Zaether O., Bajtner E., Holmadahl R., and Tarkowski A. Total abrogation of collagen II-induced arthritis and the B cell response to type II collagen using suboptimal doses of a topoisomerase II antagonist. Ann. Rheum. Dis. 61 (2002) 829-831
69. Verdenqh M., and Tarkowski A. Impact of topoisomerase II inhibition on cytokine and chemokine production. Inflamm. Res. 52 (2003) 148-153
70. Vidal O., Kindblom L.G., and Ohlsson C. Expression and localization of estrogen receptor-beta in murine and human bone. J. Bone Miner. Res. 14 (1999) 923-929
71. Vidal O., Lindberg M.K., Hollberg K., Baylink D.J., Lubahn D.B., Mohan S., Gustafsson J.A., and Ohlsson C. Estrogen receptor specificity in the regulation of skeletal growth and maturation in male mice. Proc. Natl. Acad. Sci. U S A. 97 (2000) 5474-5479
72. Viereck V., Grundker C., Blascheke S., Niederkleine B., Siggelkow H., froch K.-H., Raddatz D., Emons G., and Hofbauer L. Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J. Clin. Endocrinol. Metab. 88 (2003) 4206-4213
73. Weinstein R.S., and Manolagas S.C. Apoptosis and osteoporosis. Am. J. Med. 108 (2000) 153-164
74. Weinstein R.S., Jilka R.L., Parfitt A.M., and Manolagas S.C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Invest. 102 (1998) 274-282
75. Wood L.J., Nail L.M., Perrin N.A., Elsea C.R., Fisher A., and Drucker B.J. The cancer chemotherapy drug etoposide (VP-16) induces proinflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy-related symptoms. Biol. Res. Nurs. 8 (2006) 157-169
76. Zallone A. Direct and indirect estrogen actions on osteoblasts and osteoclasts. Ann. N.Y. Acad. Sci. 1068 (2006) 173-179
77. Zhang Y., Touneksti O., Akerman B., Goodyer C., and LeBlanc A. 17-beta-estradiol induces an inhibitor of active caspases. J. Neurosci. 21 (2001) RC176
78. Zheng A., Kallio A., and Härkönen P. Tamoxifen-induced rapid death of MCF-7 breast cancer cells is mediated via ERK signaling and can be abrogated by estrogen. Endocrinology 148 (2007) 2764-2777